Chitinase-3-Like-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Chitinase-3-Like-1 (YKL-40/CHI3L1; UniProt P36222), expressed in HEK293 cells. Suited for carbohydrate-binding assays, ELISA standard curve generation, antibody validation, and studies of tissue remodeling and inflammatory signaling.
Expression system
HEK293
Cat. #
REC-Chitinase3Like1

In stock

SKU
REC-Chitinase3Like1
$498.00

Target Overview

Chitinase-3-Like-1 (CHI3L1; UniProt P36222), also widely known as YKL-40 and cartilage glycoprotein 39 (CGP-39), is a 383-amino-acid secreted lectin belonging to the glycoside hydrolase family 18. Despite strong sequence homology to chitinases, CHI3L1 lacks chitinase catalytic activity; it binds chitin and chitin-like polysaccharides through a conserved carbohydrate-binding domain without hydrolyzing the glycosidic bond. The protein is naturally secreted into the extracellular space, and the HEK293 expression system used here supports proper N-glycosylation and folding, making the recombinant product appropriate for binding studies, receptor interaction assays, and as a reference standard in quantitative immunoassays. This recombinant covers the full-length mature human sequence (383 residues) and is suitable for several core research applications: generating standard curves in CHI3L1/YKL-40 ELISAs, performing chitin and heparin binding-affinity measurements, and establishing dose-response baselines in cell-based signaling studies (e.g., AKT1 pathway activation in colonic epithelial models). Because it is expressed in a human cell line, glycan-dependent interactions with receptors or matrix components are more likely to be preserved than in E. coli- or insect-cell-derived preparations. Researchers validating detection reagents can use this recombinant as a defined positive-control antigen alongside the matched Triple Point Biologics antibody (SKU: RP-Chitinase3Like1), which has been validated for Western blot against human CHI3L1. The pairing provides a traceable, internally consistent system for confirming antibody specificity and establishing signal-to-noise benchmarks before moving to complex biological matrices such as synovial fluid, cerebrospinal fluid, or plasma.

Background

CHI3L1 (YKL-40) is a secreted carbohydrate-binding protein expressed by macrophages, chondrocytes, synovial cells, hepatic stellate cells, and several epithelial cell types. It is classified as a chitinase-like lectin: the active-site glutamate required for glycosidic bond hydrolysis is replaced, abolishing enzymatic activity while preserving high-affinity polysaccharide binding. This structural feature makes CHI3L1 an informative research model for studying lectin–ligand interactions and glycan-mediated cell signaling without the complication of substrate turnover. At the cellular level, CHI3L1 has been characterised as a regulator of Th2-skewed inflammation, modulating allergen sensitization, dendritic cell accumulation, and M2 macrophage differentiation. In intestinal models, it mediates AKT1-dependent IL-8 production in colonic epithelial cells and has been shown to facilitate invasion of pathogenic enteric bacteria into colonic mucosa. In pulmonary contexts, it contributes to macrophage-mediated bacterial killing and modulates hyperoxia-induced epithelial apoptosis, making it a subject of investigation in lung injury and infection research. CHI3L1 has attracted substantial interest as a fluid-phase biomarker whose circulating or CSF concentrations correlate with disease activity across a range of conditions studied in basic and translational research. Sha et al. (2026, PeerJ) reviewed CHI3L1 biology specifically in the context of Alzheimer's disease pathology and discussed it as a research target for drug targeting studies. Donmez et al. (2026, J Proteomics) identified CHI3L1 among plasma and CSF proteomic signatures of Alzheimer's disease using explainable AI approaches, highlighting its presence in multi-analyte discovery panels. In rheumatology, Khmelevskaya et al. (2026, J Rheumatol) used single-cell and spatial omics to map disease-specific synovial landscapes in rheumatoid and psoriatic arthritis, an area where CHI3L1 has historically been studied given its original identification as a 39 kDa synovial glycoprotein. Ekström et al. (2026, Cardiovasc Diabetol) included CHI3L1 in targeted proteomics of extreme vascular phenotypes in type 1 diabetes, and Eckerström et al. (2026, Ticks Tick Borne Dis) examined CSF markers including CHI3L1 in relation to cognitive outcomes following tick-borne encephalitis. Collectively, these published studies position CHI3L1 as a broadly investigated secreted protein at the intersection of innate immunity, tissue remodeling, and neuroinflammation research. Recombinant CHI3L1 expressed in HEK293 cells provides researchers with a structurally representative antigen and functional reagent for in vitro experimentation across these areas.

Applications

  • Chitin- and heparin-binding affinity assays (SPR, BLI, or pull-down format) using recombinant CHI3L1 as the analyte or ligand
  • ELISA standard curve generation for quantification of CHI3L1/YKL-40 in plasma, serum, synovial fluid, or CSF samples
  • Antibody specificity validation by Western blot and dot-blot, paired with matched Triple Point Biologics antibody RP-Chitinase3Like1
  • Receptor binding and competition assays to map CHI3L1 interaction partners on macrophage or epithelial cell surfaces
  • AKT1 pathway activation studies in colonic or pulmonary epithelial cell lines stimulated with defined concentrations of recombinant protein
  • Macrophage polarisation (M2) assays examining cytokine output following CHI3L1 treatment in primary human monocyte-derived macrophages
  • Competitive inhibition studies to identify small-molecule or carbohydrate-based blockers of CHI3L1 chitin-binding activity
  • Immunohistochemistry positive-control tissue standard preparation using recombinant CHI3L1 as a spike-in or coating antigen

References

  1. Sha Y et al. The role of YKL-40 in Alzheimer's disease pathology and drug targeting. PeerJ. 2026. doi:10.7717/peerj.21361. PMID: 42291413
  2. Donmez TB. From prediction to mechanism: Explainable AI uncovers plasma and CSF proteomic signatures of Alzheimer's disease. J Proteomics. 2026. doi:10.1016/j.jprot.2026.105698. PMID: 42297098
  3. Khmelevskaya A et al. Single-Cell and Spatial Omics Uncover Disease-Specific Synovial Landscapes in Rheumatoid and Psoriatic Arthritis. J Rheumatol. 2026. doi:10.3899/jrheum.2026-0375. PMID: 42297438
  4. Ekström O et al. Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study. Cardiovasc Diabetol. 2026. doi:10.1186/s12933-026-03261-6. PMID: 42323624
  5. Eckerström M et al. Cognitive outcome in relation to cerebrospinal fluid markers of neuronal and glial cell damage: A prospective study of tick-borne encephalitis. Ticks Tick Borne Dis. 2026. doi:10.1016/j.ttbdis.2026.102673. PMID: 42314471

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; macrophage/neutrophil granules

Frequently Asked Questions

What molecular weight does recombinant CHI3L1 / YKL-40 run at on SDS-PAGE?

The unglycosylated mature CHI3L1 sequence predicts ~40 kDa, but because this recombinant is expressed in HEK293 cells and carries native-like N-glycosylation, it typically migrates at 42–45 kDa under reducing SDS-PAGE conditions. Glycosylation heterogeneity can produce a slightly diffuse band; this is expected and not a sign of degradation. Our lot-release SDS-PAGE confirms >90% purity at this position. If you are running a denaturing Western blot with RP-Chitinase3Like1, load 20–50 ng per lane and expect the band in the 42–45 kDa window.

Does recombinant CHI3L1 have chitinase enzymatic activity or is it catalytically inactive?

CHI3L1 is catalytically inactive despite belonging to glycoside hydrolase family 18. A glutamate residue critical for hydrolysis in true chitinases is substituted in CHI3L1, abolishing glycosidic bond cleavage. This recombinant therefore will not hydrolyze 4-methylumbelliferyl-β-D-N,N′-diacetylchitobioside (4-MU-chitobiose) or similar fluorogenic chitinase substrates. Its utility lies in chitin-binding affinity assays, heparin-binding studies, receptor interaction experiments (e.g., IL-13Rα2, CRTH2), and as a quantitative ELISA standard — not in enzymatic activity readouts.

What substrate or binding assay should I use to confirm recombinant CHI3L1 is functional?

Because CHI3L1 lacks hydrolytic activity, functionality is best confirmed by chitin-bead pull-down or surface plasmon resonance (SPR) against chitin oligosaccharides (e.g., (GlcNAc)₄–(GlcNAc)₆). Heparin-affinity chromatography retention is a complementary assay — CHI3L1 binds heparin with reported Kd in the low-nanomolar range. For cell-based work, dose-dependent induction of IL-8 or MMP production in fibroblasts (starting at 100–500 ng/mL) serves as a functional readout. A negative result in a 4-MU-based chitinase assay is, paradoxically, also consistent with intact recombinant identity.

What buffer and storage conditions are recommended for recombinant CHI3L1 long-term stability?

This recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. Aliquot immediately upon receipt and store at −20 °C; avoid repeated freeze-thaw cycles, which can cause aggregation and reduce binding activity. For working dilutions, PBS or HEPES-buffered saline (pH 7.2–7.4) supplemented with 0.1% BSA is suitable. The protein is stable at 4 °C for up to 72 hours after thawing. Do not dilute below ~10 µg/mL in carrier-free buffer without BSA supplementation, as surface adsorption losses become significant at sub-microgram concentrations.

What starting concentration of recombinant CHI3L1 should I use for a YKL-40 ELISA standard curve?

For a standard ELISA sandwich assay, a top standard of 10–20 ng/mL with 2-fold serial dilutions down to ~0.156 ng/mL covers the typical serum and synovial fluid dynamic range reported in the literature. Prepare standards in the same matrix used for unknowns (e.g., 1% BSA in PBS for buffer-based assays, or charcoal-stripped serum for clinical samples) to minimize matrix mismatch. Stock concentration should be verified by absorbance at 280 nm (ε calculated from sequence) or BCA assay before generating the curve. Lot-to-lot CV on our release standards is ≤8%.

Can I use recombinant CHI3L1 as a Western blot positive control with the RP-Chitinase3Like1 antibody?

Yes — this recombinant was validated specifically alongside RP-Chitinase3Like1 (/anti-chitinase-3-like-1-rabbit-polyclonal-antibody) for this purpose. Load 20–50 ng of recombinant per lane on a 10–12% SDS-PAGE gel under reducing conditions; the antibody detects a clean band at 42–45 kDa. Use RP-Chitinase3Like1 at 1:1,000–1:2,000 dilution with standard HRP-conjugated anti-rabbit secondary. This pairing is also useful for antibody lot validation: consistent signal intensity and band position across recombinant lots confirms antibody performance is stable.

How much recombinant CHI3L1 should I load to optimize a positive control lane for RP-Chitinase3Like1 immunoblot?

20 ng per lane is sufficient for a clean, non-saturating signal with RP-Chitinase3Like1 at 1:1,000 dilution using standard ECL detection. If you are using a highly sensitive substrate (e.g., femtogram-range ECL), reduce loading to 5–10 ng to avoid signal saturation. Run the recombinant lane adjacent to your cell lysate to confirm co-migration at 42–45 kDa; note that endogenous CHI3L1 in lysates from high-expressing lines (e.g., MDA-MB-231, U87) may appear slightly higher due to differential glycosylation. The recombinant band remains the most reliable MW reference for this target.

What dose range of recombinant CHI3L1 is appropriate for dose-response cell stimulation experiments?

Published dose-response studies report detectable downstream signaling (AKT, ERK phosphorylation; IL-8 secretion) starting at 50–100 ng/mL, with maximal or near-maximal effects typically observed at 500–1,000 ng/mL in fibroblast and macrophage models. A practical starting series is 0, 50, 100, 250, 500, and 1,000 ng/mL in complete media. The recombinant's endotoxin level is <0.1 EU/µg by LAL, so cytokine responses at these concentrations are attributable to CHI3L1 activity rather than LPS contamination — an important control point to document in the methods. Include a heat-inactivated aliquot as negative control.

Validation imagery coming soon

Western blot validation figures for REC-Chitinase3Like1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →